-
Mashup Score: 0How Groundbreaking ADCs Are Helping More Patients With MBC - 9 month(s) ago
The experts discuss current approaches in the sequencing of antibody-drug conjugates, which have been changing the treatment landscape for patients with metastatic breast cancer.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
Source: education.cmeinstitute.comCategories: Latest Headlines, PsychiatryTweet-
Measurement-based care (#MBC) practices are front and center in this review of diagnostic and treatment fundamentals for tardive dyskinesia. Earn free #CME credit ➡️ https://t.co/1gGEKubzGv https://t.co/Yv9RVDYJDU
-
-
Mashup Score: 0
Shannen Doherty, who was diagnosed with stage 4 breast cancer, wrote on Instagram: “The turmoil….. the timing of it all…. This is what cancer can look like.”
Source: PeoplemagCategories: Hem/Oncs, Latest HeadlinesTweet-
Thank you #ShannenDoherty for sharing your experience with breast cancer brain metastases, a common occurrence in #MBC. Awareness can do nothing but help! We try hard to increase awareness, clinical research and industry engagement in this space. #bcsm https://t.co/KFryd71LSp
-
-
Mashup Score: 13Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
ASCO-SEP 2022 Digital SubscriptionA comprehensive program for your self-assessment needs includes all-digital SEP® content (22 chapters + more chapter questions), an updated Question Bank, and additional educational resources. Subscribe today!
Source: meetings.asco.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @DFCI_BreastOnc: @DrHBurstein provided #ASCO23 highlights of #MetastaticBreastCancer #mbc https://t.co/PeIPg80FWw https://t.co/dRMY4hwM…
-
-
Mashup Score: 4Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
ASCO-SEP 2022 Digital SubscriptionA comprehensive program for your self-assessment needs includes all-digital SEP® content (22 chapters + more chapter questions), an updated Question Bank, and additional educational resources. Subscribe today!
Source: meetings.asco.orgCategories: Latest Headlines, Oncologists2Tweet-
RT @DFCI_BreastOnc: @DrHBurstein provided #ASCO23 highlights of #MetastaticBreastCancer #mbc https://t.co/PeIPg80FWw https://t.co/dRMY4hwM…
-
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
ASCO-SEP 2022 Digital SubscriptionA comprehensive program for your self-assessment needs includes all-digital SEP® content (22 chapters + more chapter questions), an updated Question Bank, and additional educational resources. Subscribe today!
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Honored to be discussing 3 impactful abstracts on tailoring 1st line ET+CDK4/6i at #MBC oral abstract session at 11:30 in Hall B1 #ASCO23. Amazing lineup of speakers & discussants! @ErikaHamilton9 @stolaney1 @DrDawnHershman & more https://t.co/DAHE9VRUUj https://t.co/9Kg7pB8UWK
-
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
AuthorsErika P. HamiltonSarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TNErika P. Hamilton, Ololade Dosunmu, Mythili Shastry, Lindsey Finney, Dalila B. Sellami, David W. Sternberg, Vance Wright-Browne, Deborah Toppmeyer, William R Gwin, J. Thaddeus Thaddeus, Jennifer L. Cultrera, Nusayba Ali Bagegni, Katia Khoury, Arielle Lutterman Heeke, Yuan YuanOrganizationsSarah Cannon…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Join me today in Hall B1 at 11:30am for #MBC oral abstracts and the results from a recent Phase 2 study of HER3-DXd in patients with metastatic #bcsm! #ASCO23 https://t.co/qEG1PR4RPJ
-
-
Mashup Score: 0Trastuzumab Deruxtecan Maintains Survival Advantage Over T-DM1 After Years HER2+ mBC - 12 month(s) ago
Trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in overall versus TDM-1 as well as a continued PFS benefit, according to Sara A. Hurvitz, MD.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with HER2+ metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan-nxki. #bcsm #mBC https://t.co/8mP8af4Irb
-
-
Mashup Score: 1
Comprehensive insight to the treatment armamentarium for patients with HR+/HER2-low metastatic breast cancer and factors that help inform optimal sequencing.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Comprehensive insight to the treatment armamentarium for patients with HR+/HER2-low metastatic #breastcancer and factors that help inform optimal sequencing. #mbc #bcsm | @KalinskyKevin https://t.co/PUZUuLigyz
-
-
Mashup Score: 2Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer - 1 year(s) ago
Next-line treatment strategies for patients with HR+/HER2– metastatic breast cancer (MBC) after CDKi progression are not yet optimized. This article reports on
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this real-world evaluation of post-#CDKi therapy outcomes in patients w/ HR+/HER2- #mBC, 80% stopped treatment due to disease progression. #PTEN mutations conferred poorer prognosis. @zahi_mitri https://t.co/KaTYl7sZlP https://t.co/hCXkrjF2F7
-
How groundbreaking ABCs are helping more patients with #MBC #BreastCancer https://t.co/fliq9L2llR